Former Perrigo Rx business Padagis has seen a leadership change, while Celltrion has appointed a new chief commercial officer for the US. Meanwhile, Biosimilars Canada has elected a new chair and Australia’s GBMA has welcomed fresh board members.
Padagis, the former prescription unit of Perrigo, has announced a change at the top of the organization just over 18 months after separating from its former parent.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.
